Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
2.320
-0.020 (-0.85%)
At close: Apr 9, 2026, 4:00 PM EDT
2.320
0.00 (0.00%)
After-hours: Apr 9, 2026, 8:00 PM EDT
Nasus Pharma Employees
Nasus Pharma had 7 employees as of December 31, 2025. The number of employees increased by 5 or 250.00% compared to the previous year.
Employees
7
Change (1Y)
5
Growth (1Y)
250.00%
Revenue / Employee
n/a
Profits / Employee
-$836,571
Market Cap
27.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | 5 | 250.00% | 7 | 0 |
| Dec 31, 2024 | 2 | - | - | 1 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| GSK plc | 66,841 |
| Bristol-Myers Squibb Company | 32,500 |
| Grifols | 23,737 |
| Organon & Co. | 10,000 |
| Biogen | 7,500 |
| Amarin Corporation | 80 |
NSRX News
- 15 days ago - Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update - GlobeNewsWire
- 21 days ago - BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript - GlobeNewsWire
- 22 days ago - What's Going On With Nasus Pharma Stock On Wednesday - Benzinga
- 24 days ago - Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold - GlobeNewsWire
- 4 weeks ago - Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study - GlobeNewsWire
- 4 weeks ago - Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum - GlobeNewsWire
- 6 weeks ago - Nasus Pharma to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 - GlobeNewsWire